Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis

J Antimicrob Chemother. 2021 Feb 11;76(3):582-586. doi: 10.1093/jac/dkaa490.


Background: Rifapentine exposure is associated with bactericidal activity against Mycobacterium tuberculosis, but high interindividual variation in plasma concentrations is encountered.

Objectives: To investigate a genomic association with interindividual variation of rifapentine exposure, SNPs of six human genes involving rifamycin metabolism (AADAC, CES2), drug transport (SLCO1B1, SLCO1B3) and gene regulation (HNF4A, PXR) were evaluated.

Methods: We characterized these genes in 173 adult participants in treatment trials of the Tuberculosis Trials Consortium. Participants were stratified by self-identified race (black or non-black), and rifapentine AUC from 0 to 24 h (AUC0-24) was adjusted by analysis of covariance for SNPs, rifapentine dose, sex, food and HIV coinfection. This study was registered at under identifier NCT01043575.

Results: The effect on rifapentine least squares mean AUC0-24 in black participants overall decreased by -10.2% for AADAC rs1803155 G versus A allele (Wald test: P = 0.03; false discovery rate, 0.10). Black participants with one G allele in AADAC rs1803155 were three times as likely to have below target bactericidal rifapentine exposure than black participants with the A allele (OR, 2.97; 95% CI: 1.16, 7.58). With two G alleles, the OR was greater. In non-black participants, AADAC rs1803155 SNP was not associated with rifapentine exposure. In both black and non-black participants, other evaluated genes were not associated with rifapentine exposure (P > 0.05; false discovery rate > 0.10).

Conclusions: Rifapentine exposure in black participants varied with AADAC rs1803155 genotype and the G allele was more likely to be associated with below bactericidal target rifapentine exposure. Further pharmacogenomic study is needed to characterize the association of the AADAC rs1803155 with inadequate rifapentine exposure in different patient groups.

Publication types

  • Clinical Study
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antibiotics, Antitubercular* / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Carboxylic Ester Hydrolases / genetics
  • Humans
  • Liver-Specific Organic Anion Transporter 1 / genetics
  • Pharmaceutical Preparations*
  • Polymorphism, Single Nucleotide
  • Rifampin / analogs & derivatives
  • Tuberculosis* / drug therapy
  • Tuberculosis, Pulmonary* / drug therapy


  • Antibiotics, Antitubercular
  • Antitubercular Agents
  • Liver-Specific Organic Anion Transporter 1
  • Pharmaceutical Preparations
  • SLCO1B1 protein, human
  • AADAC protein, human
  • Carboxylic Ester Hydrolases
  • Rifampin
  • rifapentine

Associated data